Quote:
Originally Posted by jeffreyn
|
Niraparib (zejula) was selected for funding at the most recent Linked Clinical Trials meeting (funding for repurposed drugs). It’s a really effective parp1 inhibitor. It was clearly the most interesting presentation, though a few others were also exciting. Look for announcement of a clinical trial to begin in 2019.